Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives
Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor. Lanifibranor's potential lies in combination therapy, offering dual metabolic and anti-fibrotic benefits independent of weight loss, complementing GLP-1 and SGLT2 agents. Inventiva has secured sufficient liquidity through Q2 2027, with contingent access to further capital, and has strengthened governance ahead of the pivotal NATiV3 Phase 3 readout.
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Inventiva (IVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Inventiva's Speculative Upside Through MASH Is Promising
Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated after its Phase 2b results. Management is narrowing its focus solely on this MASH asset. IVA's balance sheet has sufficient financing to reach that readout. But please bear in mind that it's a binary outcome.
Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript
Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript
Are You Looking for a Top Momentum Pick? Why Inventiva S.A.
Does Inventiva S.A. Sponsored ADR (IVA) have what it takes to be a top stock pick for momentum investors?
Inventiva S.A. (IVA) Presents at 44th Annual J.P.
Inventiva S.A. (IVA) Presents at 44th Annual J.P.
Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know
The consensus price target hints at a 200.6% upside potential for Inventiva (IVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Inventiva S.A. (IVA) Analyst/Investor Day Transcript
Inventiva S.A. (NASDAQ:IVA ) Analyst/Investor Day October 8, 2025 11:30 AM EDT Company Participants Mark Pruzanski Andrew Obenshain - CEO & Director Jason Campagna - President of Research and Development & Chief Medical Officer Martine Zimmermann - Executive VP of Regulatory Affairs & Quality Assurance Conference Call Participants William Alazawi Arun Sanyal Nezam H.
Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?
Inventiva (IVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript
Inventiva S.A. (NASDAQ:IVA ) Q4 2024 Earnings Call March 27, 2025 8:00 AM ET Company Participants Frédéric Cren - CEO Jean Volatier - CFO Pierre Broqua - CSO Conference Call Participants Unidentified Analyst - TD Cowen Unidentified Analyst - Jefferies & Co. Annabel Samimy - Stifel Ed Arce - HC Wainwright Jacob Mekhael - KBC Securities Rami Katkhuda - LifeSci Capital Unidentified Analyst - UBS Operator Good day and thank you for standing by.
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
